Posted by Michael Wonder on 22 Jan 2021
ICER releases draft evidence report on therapies for lupus nephritis
22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals) and belimumab (Benlysta, GlaxoSmithKline) for the treatment of lupus nephritis.
This preliminary draft marks the midpoint of ICER’s eight month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
